SPYRE THERAPEUTICS, INC. Increase (Decrease) in Accounts Payable, Trade
SPYRE THERAPEUTICS, INC. (SYRE) reported Increase (Decrease) in Accounts Payable, Trade of -$3.18 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableTrade · last filed 2026-08-04
- SPYRE THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for the quarter ending 2026-06-30 was $30.00K, a 30.43% increase year-over-year.
- SPYRE THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for the quarter ending 2026-03-31 was -$3.21M, a 206.25% decline year-over-year.
- SPYRE THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for the quarter ending 2025-12-31 was $1.45M.
- SPYRE THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for the quarter ending 2025-09-30 was $3.75M, a 93.74% increase year-over-year.
- SPYRE THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for fiscal 2025 was $8.24M.
- SPYRE THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for fiscal 2024 was -$230.00K, a 205.50% decline from fiscal 2023.
- SPYRE THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for fiscal 2023 was $218.00K.
- SPYRE THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for fiscal 2022 was -$2.64M, a 347.98% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable, Trade 3 month | Increase (Decrease) in Accounts Payable, Trade 6 month | Increase (Decrease) in Accounts Payable, Trade 9 month | Increase (Decrease) in Accounts Payable, Trade 12 month |
|---|---|---|---|---|
| 2026-06-30 | $30.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$3.18M 10-Q · filed 2026-08-04 | -$1.74M derived: sum of 3 quarters · filed 2026-08-04 | $2.01M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$3.21M 10-Q · filed 2026-05-05 | -$1.76M derived: sum of 2 quarters · filed 2026-05-05 | $1.98M derived: sum of 3 quarters · filed 2026-05-05 | $2.00M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $1.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $5.19M derived: sum of 2 quarters · filed 2026-02-19 | $5.21M derived: sum of 3 quarters · filed 2026-08-04 | $8.24M 10-K · filed 2026-02-19 |
| 2025-09-30 | $3.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $3.77M derived: sum of 2 quarters · filed 2026-08-04 | $6.79M 10-Q · filed 2025-11-04 | $2.29M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $23.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $3.05M 10-Q · filed 2026-08-04 | -$1.45M derived: sum of 3 quarters · filed 2026-08-04 | $481.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $3.02M 10-Q · filed 2026-05-05 | -$1.48M derived: sum of 2 quarters · filed 2026-05-05 | $458.00K derived: sum of 3 quarters · filed 2026-05-05 | $583.00K derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$4.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$2.56M derived: sum of 2 quarters · filed 2026-02-19 | -$2.44M derived: sum of 3 quarters · filed 2026-02-19 | -$230.00K 10-K · filed 2026-02-19 |
| 2024-09-30 | $1.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $2.06M derived: sum of 2 quarters · filed 2025-11-04 | $4.27M 10-Q · filed 2025-11-04 | $3.48M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $125.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $2.33M 10-Q · filed 2025-08-05 | $1.55M derived: sum of 3 quarters · filed 2026-02-19 | $508.00K derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $2.21M 10-Q · filed 2025-05-08 | $1.43M derived: sum of 2 quarters · filed 2026-02-19 | $383.00K derived: sum of 3 quarters · filed 2026-02-19 | $1.04M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | -$783.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-19 | -$1.83M derived: sum of 2 quarters · filed 2026-02-19 | -$1.17M derived: sum of 3 quarters · filed 2026-02-19 | $218.00K 10-K · filed 2026-02-19 |
| 2023-09-30 | -$1.04M derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2024-11-18 | -$383.00K derived: sum of 2 quarters · filed 2024-11-18 | $1.00M 10-Q/A · filed 2024-11-18 | -$2.50M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $661.00K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18 | $2.04M 10-Q/A · filed 2024-11-18 | -$1.46M derived: sum of 3 quarters · filed 2025-02-27 | |
| 2023-03-31 | $1.38M 10-Q/A · filed 2024-11-18 | -$2.12M derived: sum of 2 quarters · filed 2025-02-27 | ||
| 2022-12-31 | -$3.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$2.64M 10-K · filed 2025-02-27 | ||
| 2022-09-30 | $859.00K 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $1.06M 10-K/A · filed 2024-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |